Novartis – Talk Bio

Novartis Licenses Undisclosed Radioligand Therapy Asset from China’s Zonsen PepLib Biotech

2 weeks ago talkbio0Tagged China, Novartis, radioligand therapy, Radiopharma, Zonsen PepLib

Novartis; Zonsen PepLib; radiopharma; radioligand therapy; licensing deal; China biotech

Novartis Announces Fourth US Radioligand Therapy Facility in Winter Park, Florida

2 weeks ago talkbio0Tagged Cancer Therapeutic Procedure, Florida, Manufacturing Facilities, Novartis, radioligand therapy, Winter Park

Novartis; radioligand therapy; Florida; Winter Park; manufacturing facility; cancer treatment

Enliven’s Phase 1b ELVN‑001 leukemia pill shows competitive efficacy vs. Novartis and Terns CML TKIs

2 weeks ago talkbio0Tagged asciminib, BCR-ABL1, Contraceptives, Oral, Deep molecular response, ELVN-001, ENABLE trial, Enliven Therapeutics, Inhibitor, Measles-Mumps-Rubella Vaccine, Molecular Response, Myeloid Leukemia, Chronic, Novartis, Phase 1b, Protein-tyrosine kinase inhibitor, T315I, TERN-701, Terns, TKI, WDR20 gene

Enliven Therapeutics; ELVN-001; Phase 1b; chronic myeloid leukemia; CML; BCR-ABL1 inhibitor; major molecular response; MMR; deep molecular response; DMR; asciminib; Novartis; Terns Pharmaceuticals; TERN-701; T315I; ENABLE trial; CML pill; tyrosine kinase inhibitor; TKI; best-in-class

Novartis antibody ianalumab helps prolong control of rare blood disorder ITP

2 months ago talkbio0Tagged Antibodies, Asymmetric Septal Hypertrophy, Autoimmune thrombocytopenia, disorder control (procedure), eltrombopag, ianalumab, Inosine Triphosphate, ITP, Novartis, Promacta, rare blood disorder, treatment failure, VAYHIT2 trial

Novartis; ianalumab; primary immune thrombocytopenia; ITP; rare blood disorder; antibody; VAYHIT2 trial; time to treatment failure; disease control; ASH 2025; Promacta; eltrombopag

Novartis and Relation Therapeutics form AI-driven, multi-program atopic disease collaboration

2 months ago talkbio0Tagged * * atopic diseases * *, * * functional cell, AI-powered, Asthma, atlases, Billion, Drug Discovery, Eczema, Hypersensitivity, IL13 gene, immuno-dermatology, Lab-in-the-Loop, milestones, multi-program collaboration, Novartis

Novartis; Relation Therapeutics; AI-powered drug discovery; Lab-in-the-Loop; atopic diseases; immuno-dermatology; multi-program collaboration; asthma; allergies; eczema; allergic rhinitis; $55 million upfront; $1.7 billion milestones; functional cell atlases

Biotech interest shifting from obesity ‘halo’ to other areas like oncology and blood cancers

2 months ago talkbio0Tagged Autoimmune, biotech pivot, Halo brace, Investments, leukemia, Neoplasms, Novartis, Obesity, sector rotation

obesity drugs; biotech pivot; investment trends; Novartis; leukemia; obesity halo; sector rotation; autoimmune; oncology

Whitehawk Therapeutics Appoints Margaret Dugan as Chief Medical Officer

2 months ago talkbio0Tagged Chief Medical Officer, Chronic multifocal osteomyelitis, Clinical Trials, Dracen Pharmaceuticals, Drug Development, Margaret Dugan, Neoplasms, Novartis, Schrödinger, therapeutic autologous dendritic cells, Whitehawk Therapeutics

Whitehawk Therapeutics; Margaret Dugan; Chief Medical Officer; CMO; oncology; ADC; drug development; clinical trials; Novartis; Dracen Pharmaceuticals; Schrödinger